0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Growth Response to Growth Hormone during the First Year as a Diagnosis Criterion of Growth Hormone Deficiency

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Idiopathic growth hormone (GH) deficiency is a clinically and biologically heterogeneous condition. This study evaluates the capacity of the initial growth response to hGH therapy to distinguish certain from transient GH deficiency. Twenty-five patients having a GH peak < 10 μg/l after 2 pharmacological stimulation tests were classified according to the accuracy of the diagnosis of GH deficiency. Group 1 (n = 17) had certain GH deficiency because of pituitary stalk interruption syndrome and/or familial form. Group 2 (n = 8) had a transient GH deficiency. The mean increase in height standard deviation (SD) was 1.3 ± 0.1 (mean ± SE) and 0.5 ± 0.1 during the first and second years in group 1 and 0.4 ± 0.1 (p < 0.0005, compared to group 1) and 0.1 ± 0.2 (p < 0.025 compared to group 1) during the first and second years in group 2. During the first year of therapy, the increase in height was > 1 SD in 14 patients of group 1 and in 1 patient of group 2. In group 1, this increase was positively correlated with an increase in body mass index (r = 0.80, p < 0.01) during the first year and with target height (r = 0.60, p < 0.02) during the second year. Growth rate (SD for age) during the first year in this group was negatively correlated with the height prior to therapy (r = -0.72, p < 0.005). In group 2, the increase in height was positively correlated with the growth rate before therapy (r = 0.74, p < 0.05) during the first year and with the hGH dose (r = 0.90, p < 0.025) during the second year. We conclude that the growth response during the first year of hGH therapy, interpreted according to the height before therapy, is a good criterion of GH deficiency and that the change in weight influences the growth response in certain GH deficiency. The group of transient GH deficiency emphasizes the need to perform additional evaluations of GH secretion in children having GH deficiency without anatomical lesion and increase in height lower than 1 SD during the first year of hGH therapy.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          1663-2818
          1663-2826
          1993
          1993
          05 December 2008
          : 40
          : 4
          : 123-127
          Affiliations
          Paediatric Endocrinology Unit, Hôpital et Faculté Necker Enfants Malades, Paris, France
          Article
          183780 Horm Res 1993;40:123–127
          10.1159/000183780
          8300059
          © 1993 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 5
          Categories
          Original Paper

          Comments

          Comment on this article